Follow-Up Recommendations for Localized AL Amyloidosis
Recommended Follow-Up Schedule
- The European Hematology Association recommends initial follow-up at 6 months after diagnosis to establish baseline stability, and if stable, continue with annual follow-up evaluations for life due to the persistent risk of progression 1, 2, 3
- More frequent monitoring (every 3-6 months) may be warranted if there are any concerning symptoms or laboratory abnormalities, as suggested by the International Society of Amyloidosis 2
Laboratory Tests to Include at Each Follow-Up
- Complete blood count with differential should be performed to assess for cytopenias that might suggest bone marrow involvement, according to the American Society of Hematology 4, 5
- Serum protein electrophoresis and immunofixation should be done to detect any emerging monoclonal protein, as recommended by the European Hematology Association 1, 2
- Serum free light chain assay with ratio calculation should be performed to detect early clonal plasma cell disorders, as suggested by the International Myeloma Society 4, 5
- Renal function tests (BUN, creatinine) and calcium should be monitored to assess for end-organ damage, according to the National Kidney Foundation 2, 4
- Urinalysis and 24-hour urine protein electrophoresis and immunofixation should be done to assess for renal involvement, as recommended by the American Society of Nephrology 4, 5
Physical Examination Focus Areas
- Evaluation for signs of systemic amyloidosis including macroglossia, periorbital purpura, hepatomegaly, or peripheral neuropathy should be performed, as suggested by the European Hematology Association 1, 2
Additional Considerations
- If new symptoms develop or laboratory abnormalities are detected, consider bone marrow examination to rule out systemic progression, according to the American Society of Hematology 2, 4
- For elderly patients or those with significant comorbidities and limited life expectancy (<5 years), less intensive follow-up may be appropriate, focusing on symptom-directed evaluation rather than routine surveillance, as recommended by the European Hematology Association 1, 2
Special Circumstances
- If symptoms suggestive of progression develop between scheduled visits, prompt evaluation is warranted, according to the International Society of Amyloidosis 1, 2